Market Entry Strategy

UroPharma’s initial strategy is to bring dtb therapeutics to people with MS in the US, UK and Europe.

 

UroPharma’s own market research indicates that many people with Multiple Sclerosis MS (who are already self-catheterizing) will choose dtb therapy throughout their lives because of its effectiveness and minimal side effect profile, which translates to a potential recurring revenue stream for UroPharma.

Contact Us

Tel: +44 (0) 1603 626 960

‚Äč

Email: info@uropharma.com

Social Media

  • LinkedIn Social Icon

Linkedin.com/company/uropharma

  • Twitter

Twitter.com/UroPharma

  • Facebook

Facebook.com/bladdercontrol

©2017-2020 UroPharma, Inc. All Rights Reserved